Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940384 | 0.90 | KDM4E (0.50) | MTNR1ABACE1MTNR1BHTR2CHTR2B | |
| SCHEMBL1143252 | 0.90 | KDM4E (0.50) | MTNR1ABACE1MTNR1BHTR2CHTR2B | |
| SCHEMBL7099992 | 0.88 | MTNR1A (0.52) | MTNR1ABACE1MTNR1B | |
| SCHEMBL27330863 | 0.82 | MTNR1A (0.54) | MTNR1AMTNR1BHTR2CNQO2 | |
| SCHEMBL13612576 | 0.82 | ESR1 (0.56) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL27524529 | 0.81 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL27343133 | 0.81 | MTNR1A (0.55) | MTNR1AMTNR1B | |
| SCHEMBL30088510 | 0.81 | CYP1A2 (0.57) | MTNR1A | |
| SCHEMBL443625 | 0.81 | CYP1A2 (0.57) | MTNR1A | |
| SCHEMBL8399022 | 0.81 | LMNA (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101538201-B | Preparation method of agomelatine midbody (7-methoxyl group-1-naphthyl) acetic ester | SHANGHAI INST PHARM INDUSTRY | 2013-03-06 | — | — | CN | claimed |
| CN-119707714-A | Preparation method of 2- (7-methoxy-1-naphthyl) ethylamine hydrochloride | 苏州盛达药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-105237397-A | Preparation method for process-related impurity (E) 1-acetoxy-7-methoxynaphthalene of Agomelatine process | CHENGDU ORGANIC CHEMICALS CO | 2016-01-13 | — | — | CN | disclosed |
| CN-105237397-A | Preparation method for process-related impurity (E) 1-acetoxy-7-methoxynaphthalene of Agomelatine process | CHENGDU ORGANIC CHEMICALS CO | 2016-01-13 | — | — | CN | disclosed |
| CN-103588651-B | 2-(7-methoxy-1-naphthyl) preparation method of ethamine | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-12-02 | — | — | CN | disclosed |
| US-20140336380-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | RANBAXY LABORATORIES LIMITED (IN) | 2014-11-13 | — | — | US | disclosed |
| EP-2785681-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | Ranbaxy Laboratories Limited (IN) | 2014-10-08 | — | — | EP | disclosed |
| CN-103588651-A | Preparation method for 2-(7-methoxy-1-naphthyl)ethylamine | SHANGHAI INST PHARM INDUSTRY | 2014-02-19 | — | — | CN | disclosed |
| CN-102452951-B | Agomelatine and pharmaceutical composition thereof | TIANJIN TAIPU PHARMACEUTICAL SCI & TECH DEV CO LTD | 2014-02-19 | — | — | CN | disclosed |
| CN-1247528-C | Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same | SIRVIR LAB (FR) | 2006-03-29 | — | — | CN | disclosed |
| CN-1285817-A | Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same | ADIR (FR) | 2001-02-28 | — | — | CN | disclosed |
| CN-1048720-C | New o-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 2000-01-26 | — | — | CN | disclosed |
| CN-1127247-A | New o-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 1996-07-24 | — | — | CN | disclosed |
| EP-0530087-B1 | Naphthylethylurea and naphthylethylthiourea compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-05-03 | — | — | EP | disclosed |
| US-5318994-A | Treating melatoninergic disorders | ADIR ET COMPAGNIE (FR) | 1994-06-07 | — | — | US | disclosed |
| EP-0447285-B1 | NAPHTHALENE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1993-05-12 | — | — | EP | disclosed |
| US-5194614-A | COMPOUNDS HAVING A NAPHTHALENE STRUCTURE | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
| EP-0530087-A1 | Naphthylethylurea and naphthylethylthiourea compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-03-03 | — | — | EP | disclosed |
| EP-0447285-A1 | Naphthalene derivatives, procedure for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336380-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | MC5R, MC4R, COMT | MTNR1A 89/4885BACE1 3879/4885MTNR1B 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.